Drugs & Aging

, Volume 6, Issue 6, pp 421–425 | Cite as

Can Nonsteroidal Anti-Inflammatory Drugs Be Recommended to Prevent Colon Cancer in High Risk Elderly Patients?

  • Markos I. Koutsos
  • Steven J. Shiff
  • Basil Rigas
Leading Article


Aspirin Colon Cancer Familial Adenomatous Polyposis Piroxicam Sulindac 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Boring CC, Squires TS, Tong T. et al. Cancer statistics, 1994. CA Cancer J Clin 1994; 44: 7–26PubMedCrossRefGoogle Scholar
  2. 2.
    Seidman H, Mushinski MH, Gelb SK, et al. Probabilities of eventually developing or dying of cancer: United States. CA Cancer J Clin 1985; 35: 36–56PubMedCrossRefGoogle Scholar
  3. 3.
    DeCosse JJ, Tsioulias GJ, Jacobson JS. Colorectal cancer, detection, treatment and rehabilitation. CA Cancer J Clin 1994; 44: 27–42PubMedCrossRefGoogle Scholar
  4. 4.
    Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet 1993; 9: 138–41PubMedCrossRefGoogle Scholar
  5. 5.
    Karnes Jr WE Epidemiology and etiology of sporadic colorectal adenocarcinoma. Curr Opin Gastroenterol 1994; 10: 19–26CrossRefGoogle Scholar
  6. 6.
    Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: non-steroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 1991; 83: 355–8PubMedCrossRefGoogle Scholar
  7. 7.
    Insel PA. Analgesic antipyretics and antiinflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout. In: Goodman & Gilman’s The pharmacological basis of therapeutics. New York: Pergamon Press, 1990: 638–81Google Scholar
  8. 8.
    Higgs GA, Moncada S, Vane JR. The mode of action of antiinflammatory drugs which prevent the peroxidation of arachidonic acid. Rheum Dis Clin North Am 1980; 6(3): 675–93Google Scholar
  9. 9.
    Brooks MP, Day RO. Nonsteroidal antiinflammatory drugs —differences and similarities. NEngl J Med 1991; 324: 1716–25CrossRefGoogle Scholar
  10. 10.
    Abramson SB, Weissman G. The mechanism of action of NSAIDs. Arthritis Rheum 1989; 32: 1–9PubMedCrossRefGoogle Scholar
  11. 11.
    Karmali RA. Eicosanoids in neoplasia. Prev Med 1987; 16: 493–502PubMedCrossRefGoogle Scholar
  12. 12.
    Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575–89PubMedGoogle Scholar
  13. 13.
    Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518–23PubMedGoogle Scholar
  14. 14.
    Kubota Y, Sunouchi K, Ono M, et al. Local immunity and metastasis of colorectal carcinoma. Dis Colon Rectum 1992; 35: 645–50PubMedCrossRefGoogle Scholar
  15. 15.
    Eberhardt CE, Coffey RJ, Radhika A, et al. Upregulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183–8Google Scholar
  16. 16.
    Reddy BS, Sugie S. Effect of different levels of omega-3 and omega-6 fatty acids on azoxymethane-induced colon carcinogenesis in F344 rats. Cancer Res 1988; 48: 6642–7PubMedGoogle Scholar
  17. 17.
    Abramson S, Korchak H, Ludewig R, et al. Modes of action of aspirin like drugs. Proc Natl Acad Sci USA 1985; 82: 7227–31PubMedCrossRefGoogle Scholar
  18. 18.
    Shiff SJ, Tsai LL, Qiao L, et al. Sulindac sulfide inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT29 human colon adenocarcinoma cells. J Clin Invest. In pressGoogle Scholar
  19. 19.
    Shiff SJ, Koutsos MI, Qiao L, et al. Aspirin and other NSAIDs inhibit proliferation, alter the cell cycle distribution and induce apoptosis in HT29 colon adenocarcinoma cells. Gastroenterology. In pressGoogle Scholar
  20. 20.
    Pollard M, Luckert PH. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980; 64: 1323–7PubMedGoogle Scholar
  21. 21.
    Metzger U, Meier J, Uhlschmid G, et al. Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum 1984; 27: 366–9PubMedCrossRefGoogle Scholar
  22. 22.
    Reddy BS, Maruyama H, Kellof G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987; 47: 5340–6PubMedGoogle Scholar
  23. 23.
    Craven AP, DeRubertis FR. Effects of aspirin on 1,2-dimethyl-hydrazine-induced colonic carcinogenesis. Carcinogenesis 1992; 13:541–6PubMedCrossRefGoogle Scholar
  24. 24.
    Reddy BS, Rao CV, Rivenson A, et al. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14: 1493–7PubMedCrossRefGoogle Scholar
  25. 25.
    Rigas B, Tsioulias GJ, Allan C, et al. The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology 1994; 83: 319–23PubMedGoogle Scholar
  26. 26.
    Waddell WR, Loughry RN. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83–7PubMedCrossRefGoogle Scholar
  27. 27.
    Waddell WR, Ganser GF, Cerise EJ, et al. Sulindac for polyposis of colon. Am J Surg 1989; 157: 175–9PubMedCrossRefGoogle Scholar
  28. 28.
    Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635–9PubMedGoogle Scholar
  29. 29.
    Rigau J, Pique JM, Rubio E, et al. Effects of long term sulindac therapy for colonic polyposis. Ann Intern Med 1991; 115: 952–4PubMedGoogle Scholar
  30. 30.
    Giardello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313–6CrossRefGoogle Scholar
  31. 31.
    Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106: 362–6PubMedGoogle Scholar
  32. 32.
    Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer 1988; 48: 4399–404Google Scholar
  33. 33.
    Thun MJ, Namboodiri MM, Heath Jr CW. Aspirin use and the reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593–6PubMedCrossRefGoogle Scholar
  34. 34.
    Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993; 72: 1171–7PubMedCrossRefGoogle Scholar
  35. 35.
    Peleg II, Maibach HT, Brown SH, et al. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154: 394–9PubMedCrossRefGoogle Scholar
  36. 36.
    Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241–6PubMedGoogle Scholar
  37. 37.
    Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use and chronic diseases: a cohort study of the elderly. Br Med J 1989; 299: 1247–50CrossRefGoogle Scholar
  38. 38.
    Gann PH, Manson JE, Glynn RJ, et al. Low dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 1993; 85: 1220–4PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Markos I. Koutsos
    • 1
  • Steven J. Shiff
    • 1
    • 2
  • Basil Rigas
    • 1
    • 2
  1. 1.Division of Digestive DiseasesCornell University Medical CollegeNew YorkUSA
  2. 2.Rockefeller UniversityNew YorkUSA

Personalised recommendations